Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hwee Teoh

Showing results (81-90 of 128) with videos related to

Pageof 13
Sort By:
European Heart Journal. Quality of Care & Clinical Outcomes|February 24, 2018
Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada surveyJasmine Grenier, Lawrence A Leiter, Anatoly Langer, et al.
Circulation|September 12, 2012
MicroRNA-145 targeted therapy reduces atherosclerosisFina Lovren, Yi Pan, Adrian Quan, et al.
Heart (British Cardiac Society)|February 7, 2023
Predictors of mitral valve haemodynamics after mitral valve repair for degenerative mitral regurgitationRawan K Rumman, Subodh Verma, Vincent Chan, et al.
Diabetes Care|March 12, 2015
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trialLawrence A Leiter, Hwee Teoh, Eugene Braunwald, et al.
The Canadian Journal of Cardiology|January 25, 2022
Leaflet Resection vs Preservation for Degenerative Mitral Regurgitation: Functional Outcomes and Mitral Stenosis at 12 Months in a Randomized TrialMakoto Hibino, Arjun Pandey, Vincent Chan, et al.
Current Opinion in Cardiology|June 26, 2021
Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?Abhinav Sharma, Haya Aziz, Subodh Verma, et al.
Cardiovascular Diabetology|August 28, 2024
Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trialMarina Pourafkari, Kim A Connelly, Subodh Verma, et al.
The Journal of Thoracic and Cardiovascular Surgery|September 24, 2015
Dual antiplatelet therapy use by Canadian cardiac surgeonsBobby Yanagawa, Marc Ruel, Christopher Bonneau, et al.
Biochemical and Biophysical Research Communications|January 26, 2020
The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertensionBiswajit Chowdhury, Albert Z Luu, Vincent Z Luu, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 27, 2021
Mitral repair with leaflet preservation versus leaflet resection and ventricular reverse remodeling from a randomized trialMakoto Hibino, Nitish K Dhingra, Subodh Verma, et al.
Pageof 13

Showing results (81-90 of 128) with videos related to

Sort By:
Pageof 13
European Heart Journal. Quality of Care & Clinical Outcomes|February 24, 2018
Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada surveyJasmine Grenier, Lawrence A Leiter, Anatoly Langer, et al.
Circulation|September 12, 2012
MicroRNA-145 targeted therapy reduces atherosclerosisFina Lovren, Yi Pan, Adrian Quan, et al.
Heart (British Cardiac Society)|February 7, 2023
Predictors of mitral valve haemodynamics after mitral valve repair for degenerative mitral regurgitationRawan K Rumman, Subodh Verma, Vincent Chan, et al.
Diabetes Care|March 12, 2015
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trialLawrence A Leiter, Hwee Teoh, Eugene Braunwald, et al.
The Canadian Journal of Cardiology|January 25, 2022
Leaflet Resection vs Preservation for Degenerative Mitral Regurgitation: Functional Outcomes and Mitral Stenosis at 12 Months in a Randomized TrialMakoto Hibino, Arjun Pandey, Vincent Chan, et al.
Current Opinion in Cardiology|June 26, 2021
Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?Abhinav Sharma, Haya Aziz, Subodh Verma, et al.
Cardiovascular Diabetology|August 28, 2024
Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trialMarina Pourafkari, Kim A Connelly, Subodh Verma, et al.
The Journal of Thoracic and Cardiovascular Surgery|September 24, 2015
Dual antiplatelet therapy use by Canadian cardiac surgeonsBobby Yanagawa, Marc Ruel, Christopher Bonneau, et al.
Biochemical and Biophysical Research Communications|January 26, 2020
The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertensionBiswajit Chowdhury, Albert Z Luu, Vincent Z Luu, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 27, 2021
Mitral repair with leaflet preservation versus leaflet resection and ventricular reverse remodeling from a randomized trialMakoto Hibino, Nitish K Dhingra, Subodh Verma, et al.
Pageof 13